Clinical Development, Targeted Protein Degradation and Therapies

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Clinical Development

Targeted Protein Degradation

Therapies

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

The Pharma Data

JULY 22, 2021

The companies will equally share worldwide development costs, commercialization expenses, and profits. This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer.

Targeted Protein Degradation

Targeted Protein Degradation Therapies Clinical Trials Treatment

Monte Rosa Therapeutics raises $96m to develop protein-degrading molecules

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. In this process, protein-degrading molecules ‘co-opt’ large cellular proteins (ubiquitin ligases) to breakdown other target proteins, including those that cause cancer. “We

Targeted Protein Degradation

Targeted Protein Degradation Small Molecule Clinical Development Disease

Drug Discovery Digest

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

Monte Rosa Therapeutics raises $96m to develop protein-degrading molecules

Stay Connected